Osaka University Venture Capital Co., Ltd. has made a significant additional investment in Immunorock Corporation to support the development of its innovative oral cancer vaccine utilizing bifidobacteria.
Investment in Immunorock Corporation
On July 18, 2023, the OUVC No. 2 Investment Limited Partnership, which is managed by Osaka University Venture Capital Co., Ltd. (OUVC), headquartered in Suita City, Osaka, executed an additional investment of 835 million yen in Immunorock Corporation, which is headquartered in Chuo-ku, Kobe City. This marks the third investment following prior contributions in July 2023 and April 2024.
Target Overview
Immunorock Corporation, founded in April 2021, is a venture company that specializes in developing oral vaccines utilizing bifidobacteria. The company was established based on the research results of Professor Toshio Shirakawa from the Graduate School of Science and Technology Innovation at Kobe University. The primary focus of Immunorock is on developing a WT1 oral cancer vaccine, which leverages the properties of bifidobacteria.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Since the previous investment in April 2024, Immunorock has been conducting a Phase 1 clinical trial featuring B440, an oral cancer vaccine targeting patients with progress
Similar Deals
Catalys Pacific and SR One → Renalys Pharma, Inc.
2024
大阪大学ベンチャーキャピタル株式会社
invested in
株式会社イムノロック
in 2023
in a Series A deal
Disclosed details
Transaction Size: $1M